motrmech@metrocast.netis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this worth taking a gamble at getting in at .50 or wait on some more less than bad news in the forth quarter results coming out on Thursday .... thoughts??
Nice swing Friday, what a wild day on no news!!!
Will it get back to buy in at .20 or so.
This should fly in the early market...
NEW YORK, Jan 19, 2010 /PRNewswire via COMTEX/ ---- SIRIUS XM Radio (Nasdaq: SIRI) today announced that it ended the year with 18,772,758 subscribers, adding 257,028 net subscribers in the fourth quarter of 2009.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080819/NYTU044LOGO)
"Based on preliminary financial data, we expect to report over $100 million of free cash flow for 2009, an extraordinary improvement over the pro forma negative free cash flow of $552 million that the company experienced in 2008," noted Mel Karmazin, Chief Executive Officer, SIRIUS XM. "This is the first year in our history that we have generated positive free cash flow for the entire year. Our fourth quarter subscriber results mark two consecutive quarters of net subscriber additions for SIRIUS XM and are the highest since the third quarter of 2008. Improvements in automotive sales, conversion rates and better than anticipated self-pay churn suggest that the outlook for the auto sector and the effects of the economy on our business are beginning to improve," Mr. Karmazin added.
The company also announced that the conversion rate to a self-pay subscription from a trial included in the sale of a vehicle for the fourth quarter of 2009 was 46.4%, up from 44.2% in the fourth quarter of 2008, and that self-pay churn was 1.97% for the fourth quarter of 2009. "We expect to meet our guidance and report over $400 million in pro forma adjusted operating income, an improvement of over $500 million from the pro forma adjusted operating income for 2008, and an improvement of nearly $1 billion from the pro forma adjusted operating income for 2007, the last full year prior to the merger of SIRIUS and XM," said David Frear, Chief Financial Officer, SIRIUS XM.
The company's self-pay subscriber base increased by 247,182 in the fourth quarter to 15,703,932 subscribers, while total paid and unpaid trials included in the sale of a vehicle remained level with the prior quarter and the prior year at approximately 3.6 million.
SIRIUS XM plans to release full-year 2009 financial results in February 2010
Just hit .72 WHOOOOHOOOO
Latest news.
Press Release Source: Rosetta Genomics On Tuesday January 19, 2010, 5:55 pm
PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ: ROSG - News), a leading developer of microRNA-based molecular diagnostics, today announced that it has completed its previously announced registered direct offering with several institutional investors of approximately $5.1 million of securities. Rosetta has received net proceeds of approximately $4.5 million after deducting placement agent fees and other offering expenses. Under the terms of the financing Rosetta has sold 2,530,000 units, consisting of an aggregate of 2,530,000 ordinary shares and warrants to purchase 1,265,000 additional ordinary shares. Each unit, consisting of one ordinary share and a warrant to purchase 0.50 of an ordinary share, was sold for a purchase price of $2.00.
What a great trading day on great positive upgrades, can't wait for next week.
RTK Upgrade
Rentech initiated with a Buy at Brean Murray
Brean Murray believes Rentech is well positioned to commercialize its proven synthetic fuels technology. Target $2.50. :theflyonthewall.com
Volume should stay high.
Rosetta Genomics (ROSG Quote) should open nearly 30% lower after the company said late Wednesday that it would raise $5.1 million in a registered direct offering of units consisting of one ordinary share and a warrant to purchase one half of an ordinary share for a purchase price of $2. The 50-day average daily volume for Rosetta Genomics is 47,000, according to the Nasdaq. The stock had jumped 67% to $3.09 during Wednesday's session before details of the offering were announced.
Wow this is going nuts !!!!!
I hear that, just don't look back stocks like this is why i got out of the OTC's
Why this one is headed for .10 today...
More great info
News and FDA Updates for Radient (NYSE:RPC), S3 (OTC:SIVC), Seattle Genetics (NASDAQ:SGEN)
M.E. GarzaDecember 22, 2009 BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.
A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com
On 12/21/09, Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (NYSE:RPC) announced it has signed a 3-year marketing, sales and distribution agreement with GenWay Biotech Inc.
On 12/21/09, S3 Investment Company, Inc. (OTC:SIVC) announced the company has posted the December edition of its shareholder newsletter, which includes a review of the 2009 calendar year and the accomplishments of the company's Redwood Capital subsidiary.
On 12/21/09, Seattle Genetics, Inc. (NASDAQ:SGEN), announced it has entered into a collaboration agreement with GlaxoSmithKline (GSK) under which GSK will pay an upfront fee of $12 million for rights to utilize Seattle Genetics´ antibody-drug conjugate (ADC) technology with multiple antigens to be named by GSK.
Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
Disclosure: No positions.
WOW nice spread today, needs to keep it up this is when it's fun!!!!
Could open higher on Tuesday, might run to .50...
OK, not bashing here but why is this listed as the EPS is-4.00 more than the current stock price is worth?
Doesn't that make this worth zero??
More big chunks bought at the end of the day, interesting.
I think the reason of the lower numbers is that the money that was taken out on loans should be paid first, which will cut into the bottom line the numbers seem more relistic than the ones in August and could be more in line with the market conditions IMHO.
Nice post thanks.
Just a cheap penny stock climbing its way back up.
Great news.
Thanks
Yea no kidding i love it... panic buying LOL just watch for news around the middle of January for the exit.
Good Luck.
Sounds like there is some more money to make here, at least until Jan 28.
Interesting,yes very big chunks bought at the end of the session
and no SEC filing yet so.. IMO this will trade next week until the plan comes out or a filing is placed with the SEC.
Could be fun to watch what happens with the share price.
Good Luck.
Nice, there were more buys today than sells the low price is bringing in the bulls and new volume this should help, we will see.
It is a great way to make or loose a lot of $$$ but fun to watch.
Good Luck
WOW you think after the AIG R/S that someone might rethink that move, it never helps a stock just looks better when it has a higher per share value but it is still worth only what is on the balance sheet.
Or buy on the dip for a nice run, its a pennystock always a gamble.
For those of us that want back in under $3 we might have our chance.
GL
WOW, today was nuts wish i had the day off to catch the nice spike today, great news too think it will get back to $2 or so in the next few weeks, alot of buys made today IMO.
Good Luck.
Nice, what a great spike on low volume and no news.
GL
This is nuts, i keep buying down might hold on for $3 or less to get the rest.
I agree tax losses for the end of the year, i sold ALL of my non producing stocks last week for a loss, i needed the cushion and am sick of looking at RED in my account.
Very interested on what they price them at around $3 is my guess.
Nice, some good volume and nice price swing today too.
Pretty dull stock to watch, 00001 then 00002 day after day.
Agreed, better to take a loss than have zero, Q's can really stink.
NEWS
ClearFuels Technology Inc. (“ClearFuels”) and Rentech, Inc. (NYSE AMEX:RTK) jointly announced today that they have been selected to receive up to $23 million as a grant from the U.S. Department of Energy (“DOE”) to construct a biomass gasifier at Rentech’s Energy Technology Center (“RETC”) in Denver. The gasifier will be integrated with Rentech’s Product Demonstration Unit (“PDU”) for the production of renewable synthetic fuels from biomass. The proposed project team led by ClearFuels includes Rentech, URS, Linde/Hydro-Chem, Hawaiian Electric Company, National Renewable Energy Lab (“NREL”), and Hawaii Natural Energy Institute (“HNEI”).
The grant, which is subject to final negotiation of documents with the DOE, will be used to manufacture and install at RETC a 20 ton-per-day ClearFuels biomass gasifier designed to produce synthesis gas (“syngas”) from sugar cane bagasse, virgin wood waste and other cellulosic feedstocks. The gasifier will be integrated with Rentech’s existing PDU, which uses the Rentech Process and UOP’s upgrading technologies to produce renewable drop-in synthetic jet and diesel fuels at demonstration scale of 10 barrels per day. This joint demonstration of an integrated bio-refinery will lead to the final design basis for commercial facilities that are expected to use the combined technologies.
Conference call on Tuesday
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the company will host a conference call on Tuesday, December 8, 2009 at 2:00 PM EST to discuss the new clinical data from its Phase 2 voreloxin program presented at the 51st Annual American Society of Hematology (ASH) Meeting in New Orleans. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team to review updated data from both its Phase 2 combination study of voreloxin and cytarabine in relapsed or refractory AML patients and the REVEAL-1 study, a Phase 2 dose regimen optimization study of single agent voreloxin in newly diagnosed elderly AML patients who are unlikely to benefit from standard induction chemotherapy.
Sliding back a little to .60